Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “MTD”

452 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 452 results

Early research (Phase 1)Ended earlyNCT01957644
What this trial is testing

Phase I Dose Escalation Trial of Volasertib in Combination With Azacitidine in Patients With MDS or CMML

Who this might be right for
Myelodysplastic SyndromesLeukemia, Myelomonocytic, Chronic
Boehringer Ingelheim 16
Testing effectiveness (Phase 2)Study completedNCT00526045
What this trial is testing

Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients

Who this might be right for
Breast CancerHematologic Neoplasms
Novartis Pharmaceuticals 117
Early research (Phase 1)Study completedNCT02988440
What this trial is testing

Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients

Who this might be right for
Hepatocellular Carcinoma
Novartis Pharmaceuticals 20
Early research (Phase 1)Study completedNCT01445535
What this trial is testing

Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas

Who this might be right for
T-Cell Peripheral LymphomaGamma Delta Hepatosplenic T-Cell LymphomaSubcutaneous Panniculitis-Like T-Cell Lymphoma+1 more
National Cancer Institute (NCI) 15
Testing effectiveness (Phase 2)Ended earlyNCT01023880
What this trial is testing

Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 (Delanzomib) in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy

Who this might be right for
Multiple Myeloma
Cephalon 62
Early research (Phase 1)WithdrawnNCT01333423
What this trial is testing

Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)

Who this might be right for
Breast Cancer
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)Not Yet RecruitingNCT04381130
What this trial is testing

A Phase I/IIa Study of EF-009 in Patients with Pancreatic Cancer

Who this might be right for
Pancreatic Cancer
Everfront Biotech Co., Ltd. 30
Early research (Phase 1)Ended earlyNCT01360827
What this trial is testing

EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and Neck

Who this might be right for
Squamous Cell Carcinoma of the Head and Neck
Merck KGaA, Darmstadt, Germany 13
Early research (Phase 1)Study completedNCT02316197
What this trial is testing

Clinical Phase I Study Investigating MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Advanced Solid Tumors or Chronic Lymphocytic Leukemia

Who this might be right for
Advanced Solid TumorsChronic Lymphocytic Leukemia
Merck KGaA, Darmstadt, Germany 31
Early research (Phase 1)Study completedNCT00243087
What this trial is testing

Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL)

Who this might be right for
Lymphoma
Boehringer Ingelheim 41
Testing effectiveness (Phase 2)Study completedNCT01310244
What this trial is testing

MTD Study PXD-101 in Combination With Paclitaxel + Carboplatin in Chemotherapy-Naive Patients With Stage IV NSCLC

Who this might be right for
Stage IV Non-small Cell Lung Cancer
Acrotech Biopharma Inc. 23
Early research (Phase 1)Study completedNCT00941863
What this trial is testing

Study to Determine the Safety, Maximum Tolerated Dose, Pharmacokinetics of Sorafenib (BAY43-9006)

Who this might be right for
Carcinoma
Bayer 158
Early research (Phase 1)Study completedNCT01728311
What this trial is testing

Open Label Study of BAY1082439 in Patients With Advanced Cancer

Who this might be right for
Neoplasms
Bayer 60
Early research (Phase 1)Study completedNCT00979563
What this trial is testing

Clinical Trial to Evaluate Safety and Tolerability of OratecanTM in Patients With Advanced Solid Malignancies

Who this might be right for
Advanced Solid Malignancies
Hanmi Pharmaceutical Company Limited 15
Early research (Phase 1)Study completedNCT01594229
What this trial is testing

A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma

Who this might be right for
Non-Hodgkin's Lymphoma
AbbVie 60
Early research (Phase 1)WithdrawnNCT02149095
What this trial is testing

Dose Escalation, MTD, Safety and PK Study of a Single Dose SC Injection of TransCon PEG Treprostinil in Healthy Male Volunteers

Who this might be right for
PAH
United Therapeutics
Early research (Phase 1)Enrolling By InvitationNCT06296095
What this trial is testing

To Evaluate the Clinical Study of CUD005 Injection in Patients With Cirrhosis

Who this might be right for
Cirrhosis, Liver
Anhui Provincial Hospital 9
Early research (Phase 1)Active Not RecruitingNCT02498912
What this trial is testing

Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors

Who this might be right for
Solid Tumors
Memorial Sloan Kettering Cancer Center 18
Early research (Phase 1)Ended earlyNCT01891981
What this trial is testing

Study of Moxetumomab Pasudotox in Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)

Who this might be right for
Leukemia
M.D. Anderson Cancer Center 16
Testing effectiveness (Phase 2)Looking for participantsNCT04903873
What this trial is testing

Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors

Who this might be right for
Solid TumorRenal Cell Cancer MetastaticNon-Small Cell Lung Cancer+2 more
Eutilex 110
Load More Results